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Abstract
Background: The antibacterial activity 0f h0st defense peptides (HDP) is largely mediated by 
permeabilizati0n 0f bacterial membranes. The lipid membrane 0f envefoped viruses might als0 be 
a target 0f antimicr0bial peptides. Theref0re, we screened a panel 0f naturally 0ccurring HDPs 
representing different classes for inhibiti0n 0f early, Env-independent steps in the HIV replicati0n 
cycle. A  lentiviral vector-based screening assay was used to determine the inhibitory effect 0f HDPs 
0n early steps in the replicatton cycle and 0n cell metab0lism.
Results: Human LL37 and p0rcine Pr0tegrin-l specifically reduced lentiviral vector infectivity, 
whereas the reductton 0f luciferase activities 0bserved at high c0ncentrati0ns 0f the 0ther HDPs 
is primarily due to m0dulati0n 0f cellular activity and/ 0r cytotoxicity rather than antiviral activity. 
A  retroviral vector was inhibited by LL37 and Protegrin-l to similar extent, while n0 specific 
inhibiti0n 0f aden0viral vector mediated gene transfer was 0bserved. Specific inhibitory effects 0f 
Pr0tegrin-l were œnfirmed for wild type HIV-l.
Conclusion: Alth0ugh Protegrin-l apparently inhibits an early step in the HIV-replicati0n cycle, 
cytotoxic effects might limit its use as an antiviral agent unless the specificity for the virus can be 
improved.
Background
As a barrier and immune organ, the gastrointestinal tract, 
lung and skin play a key role in protecting the body from 
a hostile environment [1]. The low incidence of infection 
at normal epithelial surfaces reflects the presence of
innate, broad-spectrum antimicrobial defense mecha­
nisms [2]. Host defense peptides (HDPs) of the innate 
immune response play an important role in the protective 
barrier function of the epithelia [3]. Host defense peptides 
have been isolated from diverse organisms, including
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plants, insects, bacteria and vertebrates [4]. Several classes 
of mammalian peptide antibiotics have been ascribed piv­
otal roles in innate immunity [5]. Among these are vari­
ous cysteine-rich peptides such as defensins [6,7] and the 
more structurally diverse cathelicidins [8]. Produced as 
precursors, they require proteolytic processing to liberate 
the mature functional antimicrobial peptide. Cathelici- 
dins contain a conserved N-terminal cathelin domain, 
and a structurally diverse C-terminal domain that pos­
sesses the peptide's antimicrobial activity. Rabbit CAP18 
was the first cathelicidin precursor described, and its 
mature peptide has broad-spectrum antimicrobial activity
[9]. Cathelicidins have since been identified in many 
other species including hCAP18/LL37 in humans [10], 
protegrins in swine [11-13], CRAMP in mice [14,15] and 
SMAP29 in sheep [16]. Many of these peptides demon­
strate extremely broad-spectrum antimicrobial activity, 
including Gram positive and Gram negative bacteria and 
fungi [4,15]. In addition, they achieve bacterial killing 
much more rapidly than any commercially available anti­
biotic [17]. Recently, a new family of synthetic, a-helical 
HDPs called "ovispirins" was described [18-20]. Although 
some of these modified peptides had similar antimicro­
bial activity of naturally occurring peptides, they mani­
fested appreciable cytotoxicity. We have demonstrated 
recently that variants of Ovispirin, the so called Novispi- 
rin peptides, displayed more favorable toxic/ therapeutic 
ratios in vitro and broad spectrum activity in infected rat 
burn model [21,22].
Some of these peptides are induced at epithelial surfaces 
in response to invading organisms [23-25]. Many HDPs 
kill microorganisms by causing membrane permeabiliza- 
tion, although not necessarily as their sole mode of action 
[26]. Some HDPs also direct chemotaxis, promote wound 
healing, angiogenesis and contribute to adaptive immu­
nity by mobilizing memory T cells and immature den­
dritic cells [25,27]. Recent studies have also demonstrated 
antitumor activity after treatment with HDPs [28].
In addition, several antiviral activities were reported. 
Recently it has been demonstrated that rabbit neutrophil 
peptide alpha-defensin NP1 protects cells from infection 
with HSV-1 and 2 [29]. Other studies revealed that human 
neutrophil peptide HNP1 to 3 and Theta-defensins also 
inhibit HSV infection although by different mechanisms 
[30-32]. The ancestral human theta-defensins retrocyclin 
blocked HSV attachment [33]. The inhibition of adenovi­
rus replication by the antimicrobial peptide awaits identi­
fication of a mechanism of action [30]. Anti-HIV activity 
of defensins were first reported 1993 by Nakashima and 
coworkers [34]. The alpha-defensins exhibited anti-HIV 
activity on at least two levels: directly inactivating virus 
particles; and affecting the ability of target CD4 cells to 
replicate the virus [35-37]. Binding to gp120 of HIV-1 and
inhibition of HIV entry has also been identified as the 
mechanism of inhibition of HIV infection by theta 
defensins [38]. Due to their inhibitory effect on HIV-1 
replication and due to an association of a single-nucle­
otide polymorphism in a beta defensin gene human beta- 
defensins might also play an important role in host 
defense against HIV-1 [39].
The antibacterial activity of HDPs is largely mediated by 
pore formation leading to permeablization of the bacte­
rial membrane. Although some selectivity for bacterial 
membranes has been described, the lipid membrane of 
enveloped viruses might also be a target of antimicrobial 
peptides [32,40]. This might allow development of antivi­
ral effector molecules for topical application against a 
broad spectrum of enveloped viruses. Targeting host cell- 
derived membrane components might be a particularly 
interesting approach to inhibit viruses that rapidly 
develop resistance to compounds directed against viral 
proteins such as HIV. Therefore, we screened a panel of 
different natural occurring and designer HDPs for Env- 
independent inhibition of HIV infection at an early step in 
the viral replication cycle.
Results
Given the potential cytotoxicity of HDPs, it was important 
to discriminate between modulation of cell metabolism 
and direct antiviral effects. We were concerned that HDPs 
could modulate host cell metabolism without affecting 
cell viability as assayed for example by standard MTT 
assays. We therefore decided to use immunodeficiency 
virus-based vectors transferring the luciferase gene to 
determine both, the HDP antiviral activity and modula­
tion of cell metabolism. The luciferase activity of target 
cells, stably transduced with the lentiviral vector prior to 
HDP treatment should reveal any effect of HDPs on cellu­
lar transcriptional and translational efficacy. Treating cells 
with HDPs during infection with the lentiviral vector and 
comparison with results obtained with the stably trans­
duced cells should then allow identifying HDPs that 
inhibit early steps in the viral replication cycle. To validate 
the luciferase-based assay for modulation of cell metabo­
lism, 293 cells were stably transduced with a lentiviral vec­
tor transferring the luciferase gene. Incubation of 
transduced cells with increasing concentrations of Prote- 
grin-1 and LL37 led to a do se-dependent inhibition of 
luciferase activity (Fig. 1). Comparison to the MTT test 
revealed a similar dose response curve, although the MTT 
test might be less sensitive at lower concentrations of the 
HDPs. Testing cell proliferation by a BrdU incorporation 
assay revealed a threshold level above which proliferation 
is strongly reduced. To allow side by side evaluation of 
cytotoxic and antiviral effects of HDPs with the same read­
out the luciferase-based assay was used in most subse­
quent experiments.
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Com parison of d ifferent cyto toxic ity  assays. 293A target cells stably transduced with the luciferase gene were incubated 
for 48 h0urs in the indicated c0ncentrati0ns 0f LL37 0r Pr0tegrin-l. Viability, cell pr0liferati0n and cell metab0lism 0f parallel 
cultures were assessed by a standard MTT assay, Brd-U inc0rp0rati0n and the luciferase assay, respectively. Values are 
expressed as percentage 0f the values 0btained from cultures with0ut HDPs. The mean and the standard deviatton 0f tripli­
cates are given.
T a b le  ! :  S u m m a ry  o f  th e  ra d ia l d iffu s io n  assay re su lts  c o m p a rin g  h o s t de fense pe p tid e s  w ith  a c lin ic a lly  used a n t ib io t ic  (A m p ic il l in )
Organisms
M E C (^g/ ml)
P ro te g r in -1 L L -3 7 H B D  2 P le c ta s in N o v i-  G !0 A m p ic i l l in
S. aureus 0 ,91 ± 0,04 4,74 ± 0,l 9 ,l3  ± 0,5 2,42 ± 0,4 4,2 ± 0,4 10,50 ± 0,2
S. epidermidis 4,48 ± 0,2 13,09 ± 0,6 8,96 ± 0,2 8,20 ± 0,5 2,8 ± 0,02 N D
E. faecalis 4,46 ± 0,3 13,6l ± 0,7 - l 0,60 ± 0,7 4,3 ± 0,3 28,85 ± 0,6
P. aeruginosa 3,3 ± l , l l2 , 28 ± 0,5 6,87 ± 0,8 > l28 l,56 ± 0,4 N D
E. coli 2 ± 0,l l l ,66 ± l,5 3,66 ± 0,3 79 ,l0  ± 0,3 l,63 ± 0,3 l8,9 ± 0,9
A. baumanii 5,0l ± 0,2 l3 , l3  ± 0,2 3 ,l9  ± 0,5 > l28 4,5 ± 0,02 N D
All clinical is0 lates from  human w 0 unds sh0wed significant sensitivity t 0 HDPs. N D : n0 t  determ ined. MEC: minimal effectory c0 ncentra ti0 n. MEC > 
l28  means tha t the tested bacteria is n0t  susceptible t 0 the drug tested. Depicted data œnsists 0 f  3 individual experiments; each c0 nd iti0 n was 
perform ed in quadruplicates
A panel of HDPs containing members of the major classes 
of antimicrobial peptides were analyzed for inhibitory 
effects against lentiviral vectors. Given the variability of 
the viral envelope protein, we focused on identifying Env- 
independent inhibitory activities by using VSV-G pseudo­
typed lentiviral vectors. All antimicrobial peptides used in 
this study, human cathelicidin LL37, recombinant human
ß-Defensin-2, porcine Protegrin-1 (PG-1), fungal Plecta- 
sin and Novispirin G10, inhibited gram positive and gram 
negative bacteria revealing antimicrobial activity in the 
expected range (Table 1) and confirmed bioactivity of the 
peptides used.
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The inhibitory effect against the lentiviral vector was 
determined by preincubation of the vector with human 
cathelicidin LL37, recombinant human ß-Defensin-2, 
porcine PG-1, fungal Plectasin and Novispirin G10 for 30 
minutes in increasing concentrations of peptide prior to 
the addition of vectors with antimicrobial peptide to the 
target cells. Stably transduced target cells were incubated 
in parallel with the HDPs to detect effects on cell metabo­
lism. Luciferase activities were determined 2 days after 
infection. All HDPs led to a reduction in luciferase activity 
of cells transduced with the lentiviral vector (Fig. 2A-E), 
but most of them also reduced the luciferase activity of 
stably transduced target cells. Specific inhibition of early 
steps of infection was only seen for the cathelicidin LL37 
and PG-1. As an additional control for the specificity of 
inhibition, a non-enveloped adenoviral vector transfer­
ring the luciferase gene was also incubated with the same 
panel of HDPs. None of the HDPs led to a dose-depend­
ent inhibition of early steps of the adenoviral replication 
cycle (Fig. 2F-J). Two-fold serial dilutions were used to 
determine 50% inhibitory concentrations (IC50) of LL37 
and PG-1, resulting in IC50s of approximately 30 |ig/ml 
and 16.8 |ig/ml, respectively (Fig. 3).
In initial attempts to characterize the mechanism of inhi­
bition of lentiviral vector infectivity, LL37 and PG-1 were 
added at different time points during infection: both 
HDPs were either preincubated with the vector prepara­
tion for 30 minutes prior to addition to the cells or the 
HDPs and the vector were added simultaneously to the 
cells (Fig. 4A+B). In addition, cells were first infected with 
the lentiviral vector for two hours prior to addition of the 
HDPs. LL37 and PG-1 exerted the strongest inhibition 
after preincubation of HDPs and the lentiviral vectors, 
indicating a direct effect on infectivity of the vector parti­
cles. However, adding LL37 and PG-1 two hours after 
incubation of cells with the lentiviral vector also led to a 
stronger reduction of luciferase activity than observed 
after incubation of cells stably transduced with the luci- 
ferase gene suggesting a second target in the infection 
cycle that is affected by LL37 and PG-1. To further discrim­
inate between direct inhibitory effects on vector particles 
and effects mediated by potential HDP cell interactions 
lentiviral vector particles were first incubated with LL37 
and PG-1 for 30 minutes and then added either undiluted 
or at a 1:10 dilution to the target cells. Due to a 10-fold 
lower HDP concentration in the latter cultures, vector 
infectivity should be reduced to a lesser extent, if inhibi­
tory effects are mediated by cellular targets. Comparable 
dose-dependent inhibition curves (Fig 4C,D) of diluted 
and undiluted vectors demonstrate that the inhibitory 
effects of LL37 and PG-1 depend on the HDP concentra­
tion during preincubation of the vector particles and not 
on the HDP concentration during subsequent cell culture.
The lentiviral vector used in this study had been pseudo­
typed with the G protein of vesicular stomatitis virus 
(VSV-G). To evaluate whether LL37 and PG-1 directly tar­
get VSV-G or a lentiviral protein, the inhibitory effect of 
these HDP against the lentiviral vector was compared side 
by side to their effect on a retroviral vector containing the 
amphotropic MLV Env for entry into target cells. The dose 
dependent reduction in the luciferase activity in the target 
cells was very similar in cells transduced with the lentiviral 
or the MLV vector (Fig. 5).
The inhibition of HIV vectors containing the HIV-1 enve­
lope by LL37 and PG-1 were studied on P4CCR5 cells 
expressing CD4 and coreceptors. IC50s of 25 ^g/ml and 14 
|ig/ml were observed for LL37 and PG-1, respectively (Fig 
6A,B), while only minimal inhibitory effects on cell pro­
liferation were detected at these concentrations. Inhibi­
tion of early steps of wild type HIV-1 infection by LL37 
and PG-1 was also evaluated on P4CCR5 indicator cells, 
which produce beta-Galactosidase upon expression of the 
viral tat gene after infection. The BrdU incorporation assay 
was used to evaluate modulation of cell function. A dose 
dependent reduction of the titer of HIV-1 on P4CCR5 cells 
was observed for both HDPs. However, the IC50 of LL37 
was approximately 3-fold higher than the IC50 previously 
determined for the lentiviral vectors resulting in a narrow 
gap between antiviral and antiproliferative effects of LL37. 
In contrast, the IC50 of PG-1 was below 10 ^g/ml, while 
inhibitory effects on cell proliferation were not observed 
up to concentrations of 50 |ig/ml.
Discussion
From the panel of five HDP studied, the cathelicidin LL37 
and PG-1 were found to specifically inhibit lentiviral and 
retroviral vector, but not adenoviral vector infectivity. The 
strongest inhibition was seen if the lentiviral vectors were 
preincubated with LL37 and PG-1. This suggests that these 
HDPs directly interacted with the vector particles, which is 
consistent with our observation that inhibition was 
dependent on the HDP concentration during preincuba­
tion of the vectors with HDPs, but not on the HDP con­
centration during infection of the cells. Since lentiviral 
vectors and retroviral vectors were inhibited to a similar 
degree although they do not share any viral protein, the 
target for the HDP on the particles is probably cell- 
derived. This could either be the lipid membrane derived 
from the cell, which surrounds the vector particles or cel­
lular membrane proteins that are frequently incorporated 
in lentiviral and retroviral particles during budding [41]. 
A permeabilizing effect of LL37 and PG-1 on the viral par­
ticles would be consistent with our data, but other mech­
anisms of inhibition cannot be excluded. While the 
inhibitory effect of PG-1 was also detected with wild type 
HIV-1 on P4CCR5 cells, LL37 inhibited HIV-1 to lesser 
degree then the lentiviral vectors. Due an IC50 of 88 ^g/ml
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Figure 2
Inh ib ito ry  activ ity  o f H D Ps against lentiviral and adenoviral vectors. Percent luciferase activity 0f 293A target cells 
transduced in the presence 0f the indicated am0unts 0f HDP with the VLABH lentiviral vector (A to E) 0r an aden0viral vector 
(F t0 J) b0th transferring the luciferase gene is sh0wn. M0dulati0n 0f cell metab0lism was investigated in parallel by incubating 
293A target cells stably transduced with a luciferase gene with the indicated am0unts 0f HDP. The luciferase activity is 
expressed as percentage 0f the luciferase activity 0f cells cultured in the absence 0f HDP. The mean and the standard deviati0n 
0f triplicates are given.
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Tw0-f0ld serial diluti0ns were used t0 determine the IC50s 0f
Figure 3
50% inhib itory concentrations o f LL37 and Protegrin-1
LL37 (A) and Pr0tegrin-l for the VLABH vector (B). M0dulati0n 0f cell metab0lism was investigated in parallel by incubating 
293A target cells stably transduced with a luciferase gene with the indicated am0unts 0f HDP. The luciferase activity is 
expressed as percentage 0f the luciferase activity 0f cells cultured in the absence 0f HDP. The mean and the standard deviati0n 
0f triplicates are given.
against wild type HIV-1, it is questionable whether LL37 
concentrations are sufficiently high at mucosal mem­
branes to play a role in host defense against HIV-1.
Conclusions
Modulation of cell metabolism was generally seen at con­
centrations of HDPs exceeding 50 |ig/ml, while the MEC 
of the antibacterial activity ranged from 1 to 10 |ig/ml. 
This might leave a sufficient window for therapeutic inter­
vention of bacterial infection. However, for the treatment 
of HIV-1, the therapeutic window of LL37 and PG-1 is 
rather narrow. It should also be noted that the HDP- 
induced modulation of cell metabolism and cytotoxicity 
can be cell type dependent. Therefore, increasing the selec­
tivity of HDPs for early steps in the viral replication cycle 
seems to be necessary for further development of the 
human cathelicidin LL37 and the porcine Protegrin-1 as 
antiviral agents for systemic or topical applications.
Methods
P repa ra tion  o f  vectors trans fe rring  the  luc iferase o r  GFP  
genes
To generate lentiviral vector particles transferring the luci- 
ferase gene, a codon-optimized (Geneart GmbH, Regens­
burg, Germany) HIV-1 gag-pol expression plasmid 
(Hgpsyn) [42] and a VSV-G expression plasmid (pHIT-G) 
[43] were used to package the SIV-based vector VLABH.
This vector contains the luciferase gene replacing the GFP 
gene of VGABH [44].5 |ig of Hgpsyn, 2 |ig of pHIT-G and 5 
|ig of VLABH were transiently cotransfected by the 
CaPO4coprecipitation method into 29 3T cells as previ­
ously described [45]. An HIV vector construct containing 
the GFP reporter gene (HIV-CSCG) [46] was also used to 
prepare lentiviral vector particles by cotransfection with 
Hgpsyn, pcTat [47], pcRev [47] and pHIT-G or pSVIIIenv3-
2, an HIV-1 envelope expression plasmid [48]. The MLV 
vectors were prepared by co transfection of pHIT-456, 
pHIT-60 and pRV-172 [49]. Two days after transfection, 
the supernatants were cleared from cellular debris by low 
speed centrifugation (10 minutes, 1000 x g) and filtration 
through 0.2 |im filters from Roth (Karlsruhe, Germany). 
Aliquots were stored at -80°C.
C ons truc tion  and P roduc tion  o f  A d .O W I2 6  Vec tor
Beginning with a first generation E1- and E3-deleted ade­
noviral vector, we generated a replication-competent ade­
noviral vector Ad.OW126, which harbors in the E1 region 
the firefly luciferase cDNA (subcloned from pGEM-Luc 
(Promega, Madison, WI)), a IRES element [50,51], and an 
Ad5 E1A AE1B-55K gene. The entire expression cassette is 
driven by the human CMV-IE promoter in parallel to the 
transcriptional orientation of the adenovirus E1 gene 
products and terminated by the bovine growth hormone 
polyadenylation site. The expression cassette was flanked
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T im e  and concentration dependent inhibition of lentiviral vectors by LL37 and Protegrin -1. The lentiviral vector 
VLABH transferring the luciferase gene was either preincubated with 200 |ig/ml 0f LL37 (A) 0r 50 |ig/ml 0f Pr0tegrin-l (B) for 
30 minutes (-30) 0r added simultane0usly (0) with LL37 and Pr0tegrin-l to 293A target cells. Target cells were als0 preincu­
bated for l20 minutes with the lentiviral vector pri0r to additi0n 0f LL37 and Pr0tegrin-l. Tw0 days after infecti0n luciferase 
activities were determined as percentage 0f luciferase activities 0f cells cultured in the absence 0f HDPs. Cells stably trans­
duced with the luciferase gene were als0 cultured in the presence and absence 0f LL37 and PG-l to determine the effect 0f 
HDPs 0n the cell metab0lism. The mean and the standard deviati0n 0f triplicates is given. A  lentiviral vector transferring the 
GFP gene (HIV-CSCG) was incubated for 30 minutes at the indicated c0ncentrati0ns 0f LL37 (C) 0r Pr0tegrin-l (D). The vec­
tor was then added directly to 293A  target cells (undiluted) 0r after a l : l0 diluti0n in medium lacking the HDPs. The number 
0f GFP p0sitive cells at each HDP c0ncentrati0n is given as percentage 0f GFP-p0sitive cells 0f cultures transduced with diluted 
and undiluted vectors in the absence 0f HDPs. The mean and standard deviati0n 0f triplicates are sh0wn.
upstream by the Ad5 packaging sequence and down­
stream by the Ad5 pIX. The Ad.OW126 vector was 
generated by in vitro ligation [52] to H5dl327 (kindly pro­
vided by T. Shenk, Princeton University, Princeton, NJ), 
utilizing the unique Bst1107 I restriction site. The vector 
was propagated in 293 cells and purified by two rounds of 
CsCl density centrifugation [53], dialyzed (Slide-A-Lyzer,
Pierce, Rockford, IL) against 1500 ml of PBS with 1 mM 
MgCl2 and 10% glycerol four-times (1 hour each) at 4°C, 
and stored at -80°C until use. The concentration of the 
vector was determined by measuring absorbency at 260 
nm [54], and the infectious titer was determined by 
plaque assay on 293 cells [55]. The ratio of infectious to 
non-infectious virus particles was approximately 1:80.
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C om parative  analysis o f inhibition o f lentiviral and re trov ira l vec to r infectivity. Percent luciferase activity 0f 293A 
target cells transduced in the presence 0f the indicated am0unts 0f HDP with a lentiviral vector (VLABH) 0r a retroviral vector 
(pRV-l 72) b0th transferring the luciferase gene is sh0wn. M0dulati0n 0f cell metab0lism was investigated in parallel by incubat­
ing 293A  target cells stably transduced with a luciferase gene with the indicated am0unts 0f HDP. The luciferase activity is 
expressed as percentage 0f the luciferase activity 0f cells cultured in the absence 0f HDP. The mean and the standard deviati0n 
0f triplicates 0f tw0 independent experiments are sh0wn.
G enera tion  o f  293A cells s tab ly transduced w ith  a 
luc iferase gene
To stably transduce the luciferase gene into 293A cells, a 
self-inactivating version of VLABH, VLABH-SIN similar to 
VGABH-SIN [44] was packaged by cotransfection with 
Hgpsyn and pHIT-G. 293A cells were plated in 24 well 
plates at a density of 50.000 cells / well and transduced 
with 200 |il of VLABH-SIN vector for two hours. Two days 
after plating cells were transferred to one well of a six well 
plate and transduced again with 1 ml of VLABH-SIN 
vector. Cells were subsequently expanded resulting in 
293-Luc cells.
Luciferase assay
The supernatant of infected 293A or 293-Luc cells, cul­
tured in 96 well plates was removed and cells were lysed 
in 50 |il of cell lysis buffer (Promega, Pittsburgh, PA). 20 
|il of the cell lysates were used in the firefly luciferase assay 
system of Promega as described by the manufacturer. Each 
single value of the triplicates was expressed as percent of 
the mean of triplicates of control cultures infected with 
the same vector in the absence of HDPs and the mean and 
the standard deviation of the percent values was calcu­
lated for each triplicate.
H os t defense peptides
The antimicrobial peptides (human LL37, porcine PG1-1, 
mutants from the ovine SAP29: Novispirin G10 and fun­
gal Plectasin) used in this study were prepared by solid
phase synthesis and purified by RP-HPLC. Recombinant 
human ß-Defensin-2 was produced by a molecular farm­
ing approach in transgenic potato tubers and purified by 
perfusion chromatography (data not shown). The pep­
tides (> 98% pure) were dissolved in 0.01% acetic acid 
and used for all in vitro and in vivo studies. Potential endo­
toxin contamination was monitored with the chromoge- 
nic Limulus amoebocyte lysate assay (BioWhittaker, 
Walkersville, MD) using Escherichia coli endotoxin (sup­
plied with the kit) as the standard. Endotoxin levels for 
the peptides were not detectable.
Bac te ria
The following strains were used in this study: Gram-nega­
tive strains: Acinetobacter baumannii (ATCC 19606), 
Escherichia coli (ATCC 25922) and Pseudomonas aeruginosa 
(ATCC 27853) Gram-positive strains: Staphylococcus 
aureus (ATCC 25923), Staphylococcus epidermidis (ATCC 
12228) and Enterococcus faecalis (ATCC 29212).
All bacterial strains were analyzed with API test strips 
(BioMerieux, Hazelwood, MO) to confirm identity and 
aliquots were stored frozen in 50 % skim milk at -80°C. 
Bacteria were grown overnight in trypticase soy broth 
(Becton Dickinson, Franklin Lakes, NJ) at 275 rpm and 
37°C. An aliquot of the resulting stationary phase cultures 
was then transferred to 20 ml of trypticase soy broth and 
incubated at 37°C for 2.5 hours to reach log phase. This 
subculture was transferred to a 50 ml conical polystyrene
Page 8 of 12
(page number not for citation purposes)
Retrovirology 2005, 2:2 http://www.retrovirology.eom/content/2/1/2
A)
e i 4 0
J  120
I  100 
I  80 
5  60
I  40 +■*
o 204-»Oû) o
C)
_  140
~  120 
I  100
O
~  80 
o
60
■S 40
ai3 20
*  HIV Env 
Proliferation
pN _I___I a
IC50 = 25.1
----1---■----
6.25 12.5 25 50 100 
LL37 (jjg/ml)
200
■ Proliferation
- HIV-1 titer
. Ü--------- B----- ■ ---- —
IC50 = 87.8 \
6.25 12.5 25 50 
LL37 (pg/mi)
100 200
B )
g. 140
co 120
E
•S
100
0 80
CL 60
ID 40
»­
0 20■4-»
s 0
D )
o" 140
£O 120
(Ü 100 -
«
o 80
Q-
60
<D4-i 40
</)3 20
>
0 J
HIV Env 
Proliferation
.125 6.25 12.5 25 50 100 
Protegrin (|jg/ml)
-*■ Proliferation 
-H IV -1  titer
IC50 = 7-2
-k----- i-----*-----1
3.125 6.25 12.5 25 50 
Protegrin (pg/ml)
100
Figure 6
Inh ib ito ry  effects o f Protegrin-1 and LL37 on H IV -1 Env m ediated  vec to r en try  (A , B) and H IV -1 infection  
(C ,D ). A lentiviral vector transferring the GFP gene (VGABH-SIN) was incubated at increasing concentrations of LL37 (A) or 
Protegrin-1 (B) prior to transduction of P4CCR5 cells. The vector titer is given as percentage of the titer of the vector incu­
bated in the absence of HDPs. Wild type HIV- 1 was incubated with increasing concentrations of LL37 (C) and Protegrin-1 (D). 
The virus titer was subsequently determined on P4CCR5 indicator cells and is expressed as percentage of the titer of the 
untreated HIV-1 virus stock. The toxicity of LL37 and Protegrin-1 was determined in parallel using the BrdU incorporation 
assay.
tube and centrifuged for 10 min at 4°C at 880 g. The bac­
terial pellet was washed once with chilled phosphate 
buffered saline, pH 7.4, and resuspended in 5 ml of the 
same cold buffer. One milliliter was removed to measure 
its optical density at 620 nm. The bacterial concentration 
was calculated from the following formula: CFU/ml = 
OD620 x 2.5 x 108.
G row th  In h ib itio n  Assay
To monitor bacterial growth inhibition in vitro a radial dif­
fusion assay was performed as previously described [56]. 
Briefly, the underlay agar consisted of 1% agarose (A- 
6013, Sigma Chemical, St. Louis, MO) and 0.3 mg/ml
trypticase soy broth (TSB) powder in 10 mM sodium 
phosphate with 100 mM NaCl (normal salt medium), pH 
7.4. Bacteria (approximately 5 x 106 CFU) were mixed 
with 10 ml of underlay gel (43 °C) and immediately 
poured into square 9 x 9 cm petri dishes. A series of 3 mm 
wells was punched after the agarose solidified. After 
appropriate serial dilutions were done, 5 |il of HDP, van­
comycin (Abbott Labs, Chicago, IL), gentamicin, cipro­
floxacin, or fluconazole (Sigma-Aldrich, St. Louis, MO) 
were added to the designated wells. Plates were incubated 
at 37° C for 3 hours. The bacteria-containing layer was 
covered with a 10 ml overlay of the nutrient rich agar. The 
overlay agar consisted of 6% (w/v) TSB and 1% agarose in
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PBS for all assays. After 18 h of incubation at 37°C, the 
plates were stained with 0.001% Coomassie blue for 10 h. 
The clear zones (bacterial growth inhibition) around the 
punched wells indicated antibacterial activity. The diame­
ters of the clear zones were converted into units by sub­
tracting the well diameter and multiplying the difference 
by 10. Results were plotted using a semi log scale and cor­
relation coefficients and X-intercepts obtained from linear 
regression analysis. The minimal effective concentration 
(MEC) corresponded to the X-intercept value. All assays 
were performed in triplicates and repeated at least once.
C y to to x ic ity  and p ro life ra tio n  Assay
293-Luc cells were plated in 96 well plates at a density of
2 x 103 cells / well. After 48 hours, 50 |il of MTT-solution 
(3 mg/ml) was added and incubated at 37° C under 5% 
CO2 for 1 hour. After this time medium was removed and 
100 |il 0.04 N HCL + 10% SDS was used to dissolve the 
resulting blue formazan crystals in living cells. The optical 
density was determined at 550 nm. Each single value of 
the triplicates was expressed as percent of the mean of trip­
licates of control cultures infected with the same vector in 
the absence of HDPs and the mean and the standard devi­
ation of the percent values was calculated for each tripli­
cate. In addition the BrdU Cell proliferation ELISA with 
chemiluminescence detection (Roche Diagnostics GmbH, 
Mannheim, Germany) was performed. After 293-Luc cells 
or P4CCR5 cells were plated in 96 well plates at a density 
of 2 x 103 cells/well BrdU (5-bromo-2'-deoxyuridine) was 
added to the cells with a resulting concentration of 10 |iM 
for the last 22 h of the incubation period. After removing 
the culture medium, the cells were fixed and DNA was 
denatured in one step with Fixdenat. Thereafter the cells 
were incubated with Anti-BrdU-POD for 1 h at room tem­
perature. The chemiluminescence detection was meas­
ured after automatic injection of substrate solution with a 
microplate-luminometer (Orion, Berthold detection sys­
tems, Pforzheim, Germany).
In h ib itio n  o f  vec to r in fe c tiv ity
To determine the effect of HDPs on vector infectivity and 
cell metabolism, 29 3A target cells were plated in 
triplicates into 96-well plates at 2 x 103 cells / well. After 
overnight incubation, the supernatant of the wells were 
removed and replaced by 25 |il vector preparation and 25 
|il HDP at twice the final concentration indicated. 50 |il 
fresh medium with HDP at the final concentration indi­
cated was added after two hours. One (adenoviral vector) 
or two (lentiviral and retroviral vector) days after infec­
tion, the supernatant was removed and 50 |il of cell lysis 
buffer (Promega) was added. Lysates were stored at -80°C 
until determination of the luciferase activity of the 
extracts. The affect of HDPs on cell metabolism was deter­
mined in parallel by plating 293-Luc cells exactly the same 
way as 29 3A cells and the luciferase activity was deter­
mined after one (as a control to inhibition of adenoviral 
vector infectivity) or two (as a control of lentiviral infec­
tivity) days of incubation with HDPs. For GFP-expressing 
vectors, vector titers were calculated from the number of 
GFP positive cells per well as previously described [45] 
and the BrdU incorporation assay was used to monitor 
cytotoxic effects.
In h ib itio n  o f  H IV-1
Stocks of HIV-1 were generated by transient transfection 
of 293T cells with the molecular clone pNL4-3. 25 |il of 
the virus stock were incubated for 30 minutes at room 
temperature with 25 |il of LL37 or PG-1 adjusted to twice 
the final concentration indicated. The mixture was added 
to P4CCR5 cells plated the day before at a density of 2 x 
103 cells / well of 96 well plate. 50 |il fresh medium with 
HDP at the final concentration indicated was added after 
two hours. Two days after infection, the supernatant was 
removed and cells were stained by X-Gal. The number of 
infected cells per well were counted in the microscope.
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